GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: ATI-2138 | ATI2138 | com[pound 49 [US12297203B2]
Compound class:
Synthetic organic
Comment: Modzatinib is the INN for a tyrosine kinase inhibitor with anti-inflammatory potential (WHO INN proposed list 133, 10th July 2025). It is one of the compounds claimed in Aclaris Therapeutics' patent US12297203B2, as ITK inhibitors [1]. The INN structure was matched to that of Aclaris' lead ITK/JAK3 inhibitor ATI-2138 [2]. ATI-2138 is decalred as an irreversible inhibitor.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Modzatinib (ATI-2138) was determined to be >4200-fold less potent for inhibiting the other JAK family members, JAK1, JAK2, and Tyk2 [2]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|